GleamWall
中文EN

ORKA Oruka Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 907654 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-18.1%
ROA-17.5%
ROIC (approx.)-20.6%
Asset turnover—

Leverage & solvency

Liabilities / assets2.8%
Debt / equity0.00x
Current ratio29.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$53.70M$43.26M$29.14M$27.64M$28.99M$24.09M$19.93M$25.69M
SG&A expense$8.44M$6.85M$7.29M$6.79M$5.12M$4.34M$5.16M$3.76M
Operating income-$62.14M-$50.11M-$36.43M-$34.43M-$34.10M-$28.43M-$25.09M-$29.45M
Interest expense———————$504,000
Net income-$49.97M-$41.21M-$31.82M-$29.58M-$30.28M-$24.57M-$21.00M-$28.62M
EBITDA-$62.09M-$50.06M-$36.39M-$34.40M-$34.09M-$28.41M-$25.07M—
EPS (basic)—————-0.46-0.40-1.46
EPS (diluted)—————-0.46-0.40-1.46
Weighted avg. shares (diluted)—————42.10M41.68M15.01M
Balance sheet
Cash & equivalents$191.52M$268.47M$49.52M$46.94M$91.25M$65.40M$83.57M$410.88M
Short-term investments$728.76M$605.09M$339.31M$290.11M$257.90M$263.01M$265.52M—
Current assets$941.49M$884.56M$395.25M$343.86M$355.16M$332.01M$352.08M$412.95M
PP&E, net$309,000$275,000$318,000$288,000$253,000$174,000$159,000$160,000
Total assets$1.23B$1.14B$504.48M$488.62M$509.25M$357.42M$377.11M$414.09M
Current liabilities$31.78M$22.97M$16.63M$15.37M$20.97M$12.11M$11.72M$18.04M
Total liabilities$33.88M$24.84M$17.76M$16.69M$22.46M$13.78M$12.39M$18.88M
Shareholders' equity$1.20B$1.11B$486.72M$471.93M$486.79M$343.64M$364.73M$342.37M
Shares outstanding67.23M61.07M50.17M48.72M48.38M37.45M37.44M35.00M
Cash flow statement
Operating cash flow-$44.33M-$33.15M-$23.58M-$22.59M-$21.60M-$23.14M-$20.87M—
Capital expenditure$83,000$0$73,000$63,000$99,000$34,000$13,000—
Free cash flow-$44.41M-$33.15M-$23.65M-$22.66M-$21.70M-$23.18M-$20.88M—
Investing cash flow-$159.40M-$410.95M-$14.44M-$22.02M-$122.45M$4.86M$42.87M—
Financing cash flow$126.77M$663.04M$40.60M$298,000$169.91M———
Depreciation & amortization$49,000$43,000$43,000$28,000$20,000$19,000$16,000—
Stock-based compensation$9.13M$7.28M$6.97M$4.12M$10.16M$5.08M$4.88M$9.00M

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.